These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22871127)

  • 1. Biotinylated polyacrylamide-based metal-chelating polymers and their influence on antigen recognition following conjugation to a trastuzumab Fab fragment.
    Liu P; Boyle AJ; Lu Y; Reilly RM; Winnik MA
    Biomacromolecules; 2012 Sep; 13(9):2831-42. PubMed ID: 22871127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates.
    Liu P; Boyle AJ; Lu Y; Adams J; Chi Y; Reilly RM; Winnik MA
    Biomacromolecules; 2015 Nov; 16(11):3613-23. PubMed ID: 26469142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab Fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers.
    Liu P; Cai Z; Kang JW; Boyle AJ; Adams J; Lu Y; Ngo Ndjock Mbong G; Sidhu S; Reilly RM; Winnik MA
    Biomacromolecules; 2014 Mar; 15(3):715-25. PubMed ID: 24506198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of metal-chelating polymers (MCPs) for 111In complexed via the streptavidin-biotin system to trastuzumab Fab fragments on tumor and normal tissue distribution in mice.
    Boyle AJ; Liu P; Lu Y; Weinrich D; Scollard DA; Ngo Njock Mbong G; Winnik MA; Reilly RM
    Pharm Res; 2013 Jan; 30(1):104-16. PubMed ID: 22907419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab Labeled to High Specific Activity with (111)In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells.
    Ngo Ndjock Mbong G; Lu Y; Chan C; Cai Z; Liu P; Boyle AJ; Winnik MA; Reilly RM
    Mol Pharm; 2015 Jun; 12(6):1951-60. PubMed ID: 25919639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
    Scollard DA; Chan C; Holloway CM; Reilly RM
    Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of polyglutamide-based metal-chelating polymers and their site-specific conjugation to trastuzumab for auger electron radioimmunotherapy.
    Lu Y; Ngo Ndjock Mbong G; Liu P; Chan C; Cai Z; Weinrich D; Boyle AJ; Reilly RM; Winnik MA
    Biomacromolecules; 2014 Jun; 15(6):2027-37. PubMed ID: 24838009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
    Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
    Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab labeled to high specific activity with ¹¹¹In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells.
    Chan C; Cai Z; Reilly RM
    Pharm Res; 2013 Aug; 30(8):1999-2009. PubMed ID: 23615858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
    Razumienko E; Dryden L; Scollard D; Reilly RM
    Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts.
    Hoang B; Ekdawi SN; Reilly RM; Allen C
    Mol Pharm; 2013 Nov; 10(11):4229-41. PubMed ID: 24066900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells.
    Hoang B; Reilly RM; Allen C
    Biomacromolecules; 2012 Feb; 13(2):455-65. PubMed ID: 22191486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
    Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
    J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent.
    Blend MJ; Stastny JJ; Swanson SM; Brechbiel MW
    Cancer Biother Radiopharm; 2003 Jun; 18(3):355-63. PubMed ID: 12954122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments.
    Holloway CM; Scollard DA; Caldwell CB; Ehrlich L; Kahn HJ; Reilly RM
    Nucl Med Biol; 2013 Jul; 40(5):630-7. PubMed ID: 23618841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
    Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
    Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative binding of disulfide-bridged PEG-Fabs.
    Khalili H; Godwin A; Choi JW; Lever R; Brocchini S
    Bioconjug Chem; 2012 Nov; 23(11):2262-77. PubMed ID: 22994419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
    Cho HS; Mason K; Ramyar KX; Stanley AM; Gabelli SB; Denney DW; Leahy DJ
    Nature; 2003 Feb; 421(6924):756-60. PubMed ID: 12610629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
    Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.